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This thesis describes the in vivo evaluation of orally administered extracts of 
Echinacea species, and fractions obtained from Echinacea purpurea for specific 
immunostimulatory function induced in Balb/c mice by immunization with microbial 
vaccines. Two vaccines were used for this purpose in this study.  The first vaccine 
used consisted of whole-cell formalin-killed Salmonella typhimurium vaccine, which 
is known to induce production of specific antibodies but no delayed-type 
hypersensitivity response considered as an indicator of the cell-mediated immune 
response. The second vaccine was a commercial acellular pertussis vaccine (DTaP) 
consisting of inactivated diphtheria and tetanus toxoids and native or inactivated 
virulence factors of Bordetella pertussis (the etiological agent of whooping cough) 
which is known to induce a humoral immune response but with controversial reports 
about performance in the induction of cell-mediated immunity.  Both vaccines were 
administered intraperitoneally, whereas the herbal extracts and fractions were 
administered by oral gavage.  The phytochemical profile of the ethanolic extracts of 
Echinacea purpurea, Echinacea pallida, Echinacea angustifolia and one commercial 
product “Echinacea Triplex” and three fractions prepared from Echinacea purpurea, 
  
namely polysaccharides, phenolics and alkylamides, was determined by thin-layer 
chromatography, high-performance liquid chromatography and/or by chemical 
analytical techniques.  Statistically significant increases in specific anti-Salmonella 
typhimurium serum antibody were obtained for the Echinacea purpurea, Echinacea 
angustifolia and Echinacea Triplex™ treatment groups, and also for groups receiving 
treatment with fractions obtained from Echinacea purpurea, namely, polysaccharide, 
alkylamide and phenolic fractions.  Statistically significant increases in the anti-B 
pertussis serum antibodies were also obtained in the young Echinacea Triplex™ 
group vaccinated with the DTaP vaccine.  Significant enhancement of serum 
interleukin-12 titres was observed in the Echinacea Triplex™ as well as the phenolic 
fraction treatment groups which were vaccinated with killed Salmonella typhimurium 
vaccine.  Of the groups vaccinated with the DTaP vaccine, only Echinacea Triplex™ 
displayed statistically significant increases in mean interleukin-12 titre compared to 
the placebo in both young and old groups, however Echinacea purpurea, and 
Echinacea angustifolia both displayed significant increases in mean interleukin-12 
titre in the young treatment mice.  Increases in interferon-γ levels in mice orally dosed 
with phenolic, polysaccharide or alkylamide fractions of Echinacea purpurea and 
vaccinated with the killed Salmonella typhimurium vaccine were also observed, 
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